In the BioHarmony Drug Report Database
Daypro (oxaprozin) is a small molecule pharmaceutical. Oxaprozin was first approved as Daypro on 1992-10-29. It is used to treat juvenile arthritis, osteoarthritis, and rheumatoid arthritis in the USA. The pharmaceutical is active against prostaglandin G/H synthase 1 and prostaglandin G/H synthase 2. In addition, it is known to target bifunctional epoxide hydrolase 2.
Image (chem structure or protein)